Ian W Flinn Selected Research

duvelisib

12/2019	Combination trial of duvelisib (IPI-145) with rituximab or bendamustine/rituximab in patients with non-Hodgkin lymphoma or chronic lymphocytic leukemia.
10/2019	DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.
12/2018	The phase 3 DUO trial: duvelisib vs ofatumumab in relapsed and refractory CLL/SLL.
11/2018	Duvelisib, an oral dual PI3K-δ, γ inhibitor, shows clinical activity in indolent non-Hodgkin lymphoma in a phase 1 study.
1/2018	Duvelisib, a novel oral dual inhibitor of PI3K-δ,γ, is clinically active in advanced hematologic malignancies.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Ian W Flinn Research Topics

Disease

54	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2022 - 02/2002
36	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2021 - 02/2002
23	Neoplasms (Cancer) 12/2021 - 02/2002
19	Lymphoma (Lymphomas) 12/2021 - 09/2002
17	Neutropenia 12/2021 - 09/2011
16	Follicular Lymphoma (Lymphoma, Small Cleaved Cell, Follicular) 12/2021 - 02/2004
11	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 06/2022 - 01/2005
11	Disease Progression 01/2022 - 01/2004
11	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2021 - 02/2010
9	Diarrhea 12/2021 - 03/2014
9	Pneumonia (Pneumonitis) 04/2021 - 03/2014
9	Infections 04/2021 - 08/2003
7	Hematologic Neoplasms (Hematological Malignancy) 01/2021 - 06/2013
7	Thrombocytopenia (Thrombopenia) 01/2021 - 03/2007
6	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 04/2007
6	Leukemia 01/2019 - 02/2002
5	Febrile Neutropenia 06/2021 - 12/2014
5	Nausea 12/2018 - 05/2014
5	Fatigue 03/2017 - 04/2007
4	Exanthema (Rash) 11/2018 - 09/2011
3	Residual Neoplasm 06/2022 - 01/2019
3	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 07/2021 - 06/2013
3	Sepsis (Septicemia) 04/2021 - 03/2017
3	Multiple Myeloma 01/2021 - 01/2011
3	Hodgkin Disease (Hodgkin's Disease) 01/2021 - 08/2004
3	Colitis 01/2019 - 12/2016
3	Fever (Fevers) 12/2018 - 04/2007
3	Anemia 12/2018 - 05/2014
3	Vomiting 04/2016 - 05/2014
3	Lymphadenopathy 05/2014 - 09/2006
2	Pneumocystis Pneumonia (Pneumocystis carinii Pneumonia) 04/2021 - 03/2017
2	Body Weight (Weight, Body) 01/2020 - 12/2017
2	Marginal Zone B-Cell Lymphoma (MALT Lymphoma) 10/2019 - 08/2003
2	Tumor Lysis Syndrome 01/2019 - 12/2014
2	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 01/2019 - 10/2017
2	Necrosis 01/2019 - 04/2015
2	Lymphocytosis 03/2013 - 09/2006
2	Graft vs Host Disease (Graft-Versus-Host Disease) 10/2007 - 04/2006
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2004 - 01/2003
1	Hypertension (High Blood Pressure) 01/2022
1	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 06/2021
1	Failure to Thrive 04/2021

Drug/Important Bio-Agent (IBA)

40	Rituximab (Mabthera)FDA Link 01/2022 - 02/2002
19	Cyclophosphamide (Cytoxan)FDA LinkGeneric 06/2021 - 08/2003
15	Bendamustine Hydrochloride FDA Link 01/2022 - 05/2014
15	ibrutinibIBA 01/2022 - 07/2013
12	fludarabineIBA 11/2018 - 02/2002
11	idelalisibIBA 01/2021 - 03/2013
10	Prednisone (Sone)FDA LinkGeneric 01/2021 - 08/2003
10	Vincristine (Oncovin)FDA LinkGeneric 01/2021 - 08/2003
9	obinutuzumabIBA 01/2022 - 01/2019
9	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2021 - 08/2003
8	Chlorambucil (Leukeran)FDA Link 01/2022 - 05/2006
8	Monoclonal AntibodiesIBA 01/2019 - 02/2002
7	Agammaglobulinaemia Tyrosine KinaseIBA 01/2022 - 05/2015
7	ofatumumab FDA Link 01/2019 - 01/2016
6	Transaminases (Aminotransferases)IBA 12/2021 - 03/2014
6	ibritumomab tiuxetan (Zevalin)FDA Link 06/2021 - 02/2002
5	YttriumIBA 06/2021 - 02/2002
5	duvelisibIBA 12/2019 - 01/2018
4	Chimeric Antigen ReceptorsIBA 06/2022 - 12/2017
4	axicabtagene ciloleucelIBA 01/2022 - 12/2017
3	umbralisibIBA 12/2021 - 01/2018
3	Phosphatidylinositols (Phosphatidylinositol)IBA 12/2021 - 05/2014
3	Imatinib Mesylate (Gleevec)FDA Link 07/2021 - 09/2011
3	nilotinib FDA Link 07/2021 - 09/2011
3	venetoclaxIBA 01/2021 - 01/2019
3	Proteins (Proteins, Gene)FDA Link 01/2021 - 04/2003
3	Bortezomib (Velcade)FDA Link 01/2018 - 09/2006
3	Aspartate Aminotransferases (Aspartate Transaminase)IBA 01/2018 - 05/2014
3	Biological ProductsIBA 09/2014 - 01/2004
3	Interleukin-2 (IL2)IBA 10/2007 - 12/2005
2	brexucabtagene autoleucelIBA 06/2022 - 01/2020
2	acalabrutinibIBA 01/2022 - 01/2020
2	zanubrutinibIBA 01/2022 - 10/2020
2	Phosphotransferases (Kinase)IBA 01/2021 - 05/2014
2	carfilzomibIBA 01/2021 - 05/2015
2	PanobinostatIBA 01/2021 - 05/2015
2	Lenalidomide (CC 5013)FDA Link 10/2019 - 01/2018
2	Pharmaceutical PreparationsIBA 01/2019 - 01/2015
2	R-CHOP protocolIBA 01/2019 - 02/2010
2	enasidenibIBA 01/2019 - 10/2017
2	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 12/2018 - 05/2014
2	Alanine Transaminase (SGPT)IBA 01/2018 - 05/2014
2	Alkylating AgentsIBA 01/2017 - 03/2014
2	TRU 016IBA 01/2015 - 02/2014
2	Immunoglobulins (Immunoglobulin)IBA 06/2014 - 02/2004
2	lumiliximabIBA 01/2010 - 08/2007
2	AntibodiesIBA 08/2007 - 08/2003
2	Alemtuzumab (Campath)FDA Link 01/2005 - 05/2004
2	Complement System Proteins (Complement)IBA 04/2003 - 02/2002
1	Filgrastim (Neupogen)FDA Link 06/2021
1	ublituximabIBA 04/2021

Therapy/Procedure

37	Therapeutics 01/2022 - 03/2002
16	Drug Therapy (Chemotherapy) 01/2022 - 02/2002
6	Radioimmunotherapy 06/2021 - 02/2002
4	Stem Cell Transplantation 01/2022 - 03/2002
4	Transplantation 10/2007 - 01/2005
2	Immunotherapy 01/2018 - 06/2014
1	Precision Medicine 06/2021